Skip to main content
Conference Coverage
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
03/28/2025
Juliet Gallagher
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented...
03/28/2025
Journal of Clinical Pathways
Conference Coverage
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
Laura Bray
Videos
07/23/2024
Laura Bray, MBA
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
07/08/2024
Stephen Colvill, MBA
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
News
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
Paul Fu, MD
Interview
06/17/2024
Paul Fu Jr, MD, MPH, discusses the benefits of using technology to assist health team communication practices.
Paul Fu Jr, MD, MPH, discusses the benefits of using technology to assist health team communication practices.
Paul Fu Jr, MD, MPH, discusses...
06/17/2024
Journal of Clinical Pathways
William J. Gradishar, MD
Videos
06/04/2024
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD,...
06/04/2024
Journal of Clinical Pathways
News
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways
Anna Halpern, MD
Videos
04/06/2024

Featuring Anna Halpern, MD

Featuring Anna Halpern, MD
Anna Halpern, MD, discusses her National Comprehensive Cancer Network annual conference session on how to balance inpatient and outpatient oncology care.
Anna Halpern, MD, discusses her National Comprehensive Cancer Network annual conference session on how to balance inpatient and outpatient oncology care.
Anna Halpern, MD, discusses her...
04/06/2024
Journal of Clinical Pathways
Conference Coverage
04/27/2023
Grace Taylor, MS, MA
Kimberly Bell, RN, MBA, Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic, and Danielle McLaughlin, MPH, University of California San Diego, Moores Cancer Center, highlight different strategies...
Kimberly Bell, RN, MBA, Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic, and Danielle McLaughlin, MPH, University of California San Diego, Moores Cancer Center, highlight different strategies...
Kimberly Bell, RN, MBA, Case...
04/27/2023
Journal of Clinical Pathways
News
04/21/2023
Brandon Twyford
In a presentation at the 2023 NCCN Annual Conference, Keith Argenbright, MD, Moncrief Cancer Institute in Fort Worth, TX, and Evelyn González, Fox Chase Cancer Center in Philadelphia, PA, described the benefits of mobile cancer screening...
In a presentation at the 2023 NCCN Annual Conference, Keith Argenbright, MD, Moncrief Cancer Institute in Fort Worth, TX, and Evelyn González, Fox Chase Cancer Center in Philadelphia, PA, described the benefits of mobile cancer screening...
In a presentation at the 2023...
04/21/2023
Journal of Clinical Pathways
First-Line Treatment Approaches for Metastatic Urothelial Cancer in the US
Videos
05/04/2021
Petros Grivas, MD, PhD, discusses results from a study exploring decision-making processes regarding first-line treatment choices, testing practices and treatment eligibility determinants for patients with metastatic urothelial cancer.
Petros Grivas, MD, PhD, discusses results from a study exploring decision-making processes regarding first-line treatment choices, testing practices and treatment eligibility determinants for patients with metastatic urothelial cancer.
Petros Grivas, MD, PhD,...
05/04/2021
Journal of Clinical Pathways
Real-World Impact of Leuprolide Acetate Late Dosing on Testosterone Suppression for Prostate Cancer
Videos
05/04/2021
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.
Lucio Gordan, MD, discusses...
05/04/2021
Journal of Clinical Pathways
Conference Coverage
04/16/2021
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Study results show that...
04/16/2021
Journal of Clinical Pathways
Conference Coverage
04/07/2021
Journal of Clinical Pathways
Conference Coverage
04/07/2021
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker...
04/07/2021
Journal of Clinical Pathways
Conference Coverage
04/06/2021
Journal of Clinical Pathways